# AstraZeneca PLC (AZN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AZN
## Company Profile
- Ticker: AZN
- Exchange: NASDAQ
- Sector: Small Molecule Drugs, Biologics
- Location: UK
- Tags: Biologics, Small Molecule Drugs, Oncology, Rare Disease
## Stock Data
- Close: 158.5 USD
- Market cap: 275197992328.35 USD
- Last updated: 2026-08-12
## Business Overview
AstraZeneca is a global biopharmaceutical company with deep exposure to oncology, cardiovascular, renal, metabolic disease, respiratory, and rare disease. The company has become one of the market’s strongest large-cap growth stories.
## Why The Stock Is Moving

As of Aug 12, 2026, AZN was little changed and closed at $158.50. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the UK and listed on the U.S. as an ADR, AstraZeneca has a global operating footprint across major healthcare markets. It is a multinational biopharma with broad therapeutic reach.

## Business Model

AstraZeneca relies on blockbuster medicines, strong launch execution, and a pipeline that continues to refresh growth. Investors watch oncology momentum, pipeline readouts, and whether new launches can sustain the company’s growth profile.

## Landscape Position

AstraZeneca sits near the top of the large-cap biotech/pharma landscape because it combines scale, growth, and strong R&D execution. It is less binary than smaller biotechs but still highly reactive to major oncology and pipeline news.

## Future Catalysts

- AstraZeneca’s watchlist should stay on camizestrant, datopotamab deruxtecan, and other late-stage oncology assets that can prove the company still has multiple shots on goal. The important part is whether the update changes the odds of the next milestone rather than just confirming the current story. If the event is positive, it can improve the market’s willingness to pay for the name ahead of the following catalyst.

## Recent News
- 2016-11-01 15:30 EST — [Dealing by Person Closely Associated](https://biopharmsignal.com/news/AZN/dealing-by-person-closely-associated-1bbf1542) — Source: AstraZeneca PLC
- 2016-10-31 14:19 EST — [AZ completes US Aralez agreement for Toprol-XL](https://biopharmsignal.com/news/AZN/az-completes-us-aralez-agreement-for-toprol-xl-ad465cdd) — Source: AstraZeneca PLC
- 2016-10-27 16:02 EST — [AstraZeneca Head and Neck Cancer Trials](https://biopharmsignal.com/news/AZN/astrazeneca-head-and-neck-cancer-trials-c5c3685b) — Source: AstraZeneca PLC
- 2016-10-26 06:00 EST — [Positive results in AstraZeneca Lynparza trial](https://biopharmsignal.com/news/AZN/positive-results-in-astrazeneca-lynparza-trial-3e65ba34) — Source: AstraZeneca PLC
- 2016-10-18 06:00 EST — [FDA ACCEPTS FOR REVIEW NEW DRUG APPLICATION FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR THE TREATMENT OF HYPERKALAEMIA](https://biopharmsignal.com/news/AZN/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-cyclosilicate-z-5356e13a) — Source: AstraZeneca PLC